Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
03/11/2023 12:21
* Baudax Bio Inc BXRX.OQ BXRX.O is expected to show a
fall in
quarterly revenue when it reports results
*
* Refinitiv's mean analyst estimate for Baudax Bio Inc is
for a
loss of 53 cents per share.
* The one available analyst rating on the shares is
"hold".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Baudax Bio
Inc is
$24, above its last closing price of $0.20.
This summary was machine generated November 3 at 12:21 GMT. All
figures in US dollars unless otherwise stated
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer